Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics (ANIK)
NASDAQ:ANIK
ANIK Stock Chart & Stats
$9.58
$0.27(1.72%)
At close: 4:00 PM EST
$9.58
$0.27(1.72%)
Day’s Range― - ―
52-Week Range$7.87 - $25.00
Previous CloseN/A
Volume22.29K
Average Volume (3M)106.81K
Market Cap
$138.13M
Enterprise Value$123.79M
Total Cash (Recent Filing)$53.17M
Total Debt (Recent Filing)$24.99M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 05, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding14,418,090
10 Day Avg. Volume95,025
30 Day Avg. Volume106,805
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue1.00
Enterprise Value/Gross Profit2.33
Enterprise Value/Ebitda-4.25
Forecast
1Y Price Target
$15.50Price Target Upside61.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Cost ManagementThe company's gross margin exceeded forecasts, suggesting efficient cost management.
Financial PerformanceAnika's adjusted EBITDA was better than expected, indicating a stronger than anticipated financial performance.
ValuationShares of this under-the-radar microcap are, in fact, undervalued at current levels.
Bears Say
AcquisitionsThese failures include two value destroying acquisitions, which were sold a few years after being acquired for pennies on the dollars invested.
Execution FailuresAnika has not executed on some of its key objectives in recent years and, in our view, has not optimized its communications with investors regarding the inherent value we believe we see in the business.
Investor ConfidenceThe company requires significant wins and increased transparency around its business value drivers to regain investor confidence.
Anika Therapeutics News
ANIK FAQ
What was Anika Therapeutics’s price range in the past 12 months?
Anika Therapeutics lowest stock price was $7.87 and its highest was $25.00 in the past 12 months.
What is Anika Therapeutics’s market cap?
Anika Therapeutics’s market cap is $138.13M.
When is Anika Therapeutics’s upcoming earnings report date?
Anika Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 12 days.
How were Anika Therapeutics’s earnings last quarter?
Anika Therapeutics released its earnings results on Jul 30, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.263 by $0.133.
Is Anika Therapeutics overvalued?
According to Wall Street analysts Anika Therapeutics’s price is currently Undervalued.
Does Anika Therapeutics pay dividends?
Anika Therapeutics does not currently pay dividends.
What is Anika Therapeutics’s EPS estimate?
Anika Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Anika Therapeutics have?
Anika Therapeutics has 14,418,090 shares outstanding.
What happened to Anika Therapeutics’s price movement after its last earnings report?
Anika Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.263. Following the earnings report the stock price went down -27.419%.
Which hedge fund is a major shareholder of Anika Therapeutics?
Currently, no hedge funds are holding shares in ANIK
Anika Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (61.80% Upside)
$15.50 (61.80% Upside)
Blogger Sentiment
Bullish
ANIK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.21%
12-Months-Change
Fundamentals
Return on Equity
-22.91%
Trailing 12-Months
Asset Growth
-28.54%
Trailing 12-Months
Company Description
Anika Therapeutics
Anika Therapeutics, Inc. is a global medical technology company focused on developing, manufacturing, and commercializing innovative therapeutic solutions primarily in the fields of orthopedics, pain management, and regenerative medicine. The company specializes in hyaluronic acid (HA) technologies, which are used in products ranging from joint therapies and surgical applications to wound healing and dermal fillers. Anika's core products include viscosupplements for osteoarthritis, as well as other regenerative therapies aimed at improving patient outcomes and enhancing quality of life.
ANIK Company Deck
ANIK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. There was strong performance from the Integrity product line and progress with Cingal, but notable challenges with Hyalofast's clinical trial results and a decline in overall revenue and gross margin.View all ANIK earnings summariesANIK Stock 12 Month Forecast
Average Price Target
$15.50
▲(61.80% Upside)
Technical Analysis
Ownership Overview
4.25% Insiders
12.31% Mutual Funds
0.32% Other Institutional Investors
72.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---